ACADIA Pharmaceuticals Inc. (ACAD) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lowered its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 71.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,979 shares of the biopharmaceutical company’s stock after selling 17,063 shares during the quarter. Jane Street Group LLC’s holdings in ACADIA Pharmaceuticals were worth $263,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in ACAD. Janus Henderson Group PLC acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth approximately $102,152,000. Goldman Sachs Group Inc. raised its holdings in ACADIA Pharmaceuticals by 69.9% during the second quarter. Goldman Sachs Group Inc. now owns 1,908,251 shares of the biopharmaceutical company’s stock worth $53,222,000 after purchasing an additional 785,352 shares in the last quarter. State Street Corp raised its holdings in ACADIA Pharmaceuticals by 15.8% during the second quarter. State Street Corp now owns 3,748,468 shares of the biopharmaceutical company’s stock worth $104,551,000 after purchasing an additional 510,670 shares in the last quarter. Elliott Management Corp raised its holdings in ACADIA Pharmaceuticals by 61.7% during the second quarter. Elliott Management Corp now owns 1,256,795 shares of the biopharmaceutical company’s stock worth $35,052,000 after purchasing an additional 479,413 shares in the last quarter. Finally, Sectoral Asset Management Inc raised its holdings in ACADIA Pharmaceuticals by 63.7% during the second quarter. Sectoral Asset Management Inc now owns 1,098,809 shares of the biopharmaceutical company’s stock worth $30,646,000 after purchasing an additional 427,696 shares in the last quarter. 94.02% of the stock is currently owned by institutional investors.

In related news, EVP Glenn Baity sold 37,500 shares of ACADIA Pharmaceuticals stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total value of $1,534,125.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 22.25% of the company’s stock.

ACADIA Pharmaceuticals Inc. (ACAD) opened at $28.75 on Friday. ACADIA Pharmaceuticals Inc. has a 1-year low of $25.06 and a 1-year high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.10. The business had revenue of $35.58 million for the quarter, compared to analysts’ expectations of $32.03 million. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The company’s quarterly revenue was up 571.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.61) EPS. equities analysts forecast that ACADIA Pharmaceuticals Inc. will post -2.41 earnings per share for the current fiscal year.

ACAD has been the topic of a number of research analyst reports. J P Morgan Chase & Co set a $50.00 price objective on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 5th. Piper Jaffray Companies reissued a “buy” rating and set a $61.00 price objective (up previously from $54.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, October 5th. Jefferies Group reaffirmed a “buy” rating and issued a $47.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, October 12th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, October 5th. Finally, Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $50.00 target price (up from $48.00) on shares of ACADIA Pharmaceuticals in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $47.44.

TRADEMARK VIOLATION NOTICE: “ACADIA Pharmaceuticals Inc. (ACAD) Shares Sold by Jane Street Group LLC” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/22/acadia-pharmaceuticals-inc-acad-shares-sold-by-jane-street-group-llc.html.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit